MicroRNA and the pathogenesis of ovarian cancer a new horizon for molecular diagnostics and treatment

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 4, 2012, Pages 601-615

  Kuhlmann, Jan Dominik ^a   Rasch, Jens ^a   Wimberger, Pauline ^a   Kasimir Bauer, Sabine ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

3' untranslated region; messenger RNA; microRNA; ovarian cancer; RNA induced silencing complex; target gene

Indexed keywords

ANTINEOPLASTIC AGENT; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA; MICRORNA;

CANCER CHEMOTHERAPY; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE FUNCTION; HUMAN; HYPOXIA; METASTASIS; MOLECULAR DIAGNOSIS; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; OVARIAN NEOPLASMS;

EID: 84860459020     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0847     Document Type: Review

References (133)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329: 1550-9. (Pubitemid 23332443)
2. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107. (Pubitemid 27310783)
3. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-8. (Pubitemid 44337091)
4. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;17:909-25, vii. (Pubitemid 37022148)
5. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 Consensus statements on the management of ovarian cancer: fi nal document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 (Suppl 8):viii7-12. (Pubitemid 41631227)
6. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfi sterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.
7. Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74.
8. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al. Infl uence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010;17:1642-8.
9. Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmuller G, et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol 2001;19:368-75. (Pubitemid 32112848)
10. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009;36:112-25.
11. Lee RC, Feinbaum RL, Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54. (Pubitemid 24014542)
12. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6. (Pubitemid 30130993)
13. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
14. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA ? RNA 2005;11:1753-61. (Pubitemid 41720024)
15. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60. (Pubitemid 39472426)
16. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004;14:2162-7.
17. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-9. (Pubitemid 37187272)
18. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTPdependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004;10:185-91. (Pubitemid 38129823)
19. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004;303:95-8. (Pubitemid 38055779)
20. Billy E, Brondani V, Zhang H, Muller U, Filipowicz W. Specifi c interference with gene expression induced by long, doublestranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci USA 2001;98:14428-33. (Pubitemid 33121408)
21. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP. EMBO J 2002;21:5875-85. (Pubitemid 35315285)
22. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115:209-16. (Pubitemid 37329584)
23. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115:199-208. (Pubitemid 37329583)
24. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006;21:533-42. (Pubitemid 43228008)
25. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003;100:9779-84. (Pubitemid 37087018)
26. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006;103:4034-9.
27. Vasudevan S, Steitz JA. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 2007; 128:1105-18. (Pubitemid 46427873)
28. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007;318:1931-4.
29. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol Cell 2007;28:328-36. (Pubitemid 47600007)
30. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature 2007;448:83-6. (Pubitemid 47037009)
31. Toloubeydokhti T, Bukulmez O, Chegini N. Potential regulatory functions of microRNAs in the ovary. Semin Reprod Med 2008;26:469-78.
32. Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 2011;49:1591-603.
33. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, et al. MicroRNA expression and identifi cation of putative miRNA targets in ovarian cancer. PLoS One 2008;3: e2436.
34. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profi les in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5.
35. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fi xed paraffi nembedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007;7:36.
36. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fi xed paraffi n-embedded samples. RNA 2007;13:1668-74. (Pubitemid 47481675)
37. Hoefi g KP, Thorns C, Roehle A, Kaehler C, Wesche KO, Repsilber D, et al. Unlocking pathology archives for microRNAprofi ling. Anticancer Res 2008;28:119-23.
38. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21. (Pubitemid 351853251)
39. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009;112:55-9.
40. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
41. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699-707. (Pubitemid 47437445)
42. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, et al. MicroRNA expression profi ling in human ovarian cancer: miR- 214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33. (Pubitemid 351380068)
43. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009;4:e5311.
44. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R. miRNA profi ling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011;15:1593-602.
45. Kramer S, Leeker M, Jager W. Gonadotropin levels in ovarian cyst fl uids: a predictor of malignancy ? Int J Biol Markers 1998;13:165-8. (Pubitemid 29092527)
46. Cui J, Miner BM, Eldredge JB, Warrenfeltz SW, Dam P, Xu Y, et al. Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation. BMC Cancer 2011;11:280.
47. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fi brosis. J Clin Invest 2003;112:1776-84. (Pubitemid 38063698)
48. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
49. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 2006;290:C1532-42. (Pubitemid 43830793)
50. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6. (Pubitemid 37487967)
51. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc fi nger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7:1267-78. (Pubitemid 32607360)
52. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.
53. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009;114:457-64.
54. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial- to-epithelial transition. Gynecol Oncol 2010;116:117-25.
55. Hurteau GJ, Carlson JA, Roos E, Brock GJ. Stable expression of miR-200c alone is suffi cient to regulate TCF8 (ZEB1) and restore E-cadherin expression. Cell Cycle 2009;8:2064-9.
56. Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol 2011;121:200-5.
57. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11. (Pubitemid 33041634)
58. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
59. Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anti-cancer therapy ? Cell Cycle 2008;7:188-93. (Pubitemid 351366518)
60. Mueller MT, Hermann PC, Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed) 2010;2:602-13.
61. Guo R, Wu Q, Liu F, Wang Y. Description of the CD133 + subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep 2011;25:141-6.
62. Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1 + ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol 2011;122:149-54.
63. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009;14:29-43.
64. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, et al. TWISTing stemness, infl ammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010;29:3545-53.
65. Evans CL, Abu-Yousif AO, Park YJ, Klein OJ, Celli JP, Rizvi I, et al. Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT. PLoS One 2011;6:e23434.
66. Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, et al. Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug- activating genes in vitro and in vivo. Cancer Gene Ther 2011;18:773-84.
67. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008;7:255-64. (Pubitemid 351590433)
68. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007;64:2170-80. (Pubitemid 350103108)
69. Corn PG. Hypoxic regulation of miR-210: shrinking targets expand HIF-1's infl uence. Cancer Biol Ther 2008;7:265-7. (Pubitemid 351590434)
70. He Y, Armanious MK, Thomas MJ, Cress WD. Identifi cation of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 2000;19:3422-33. (Pubitemid 30479337)
71. Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, et al. Identifi cation of a novel E2F3 product suggests a mechanism for determining specifi city of repression by Rb proteins. Mol Cell Biol 2000;20:3626-32. (Pubitemid 30243908)
72. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, et al. Regulation of ovarian cancer progression by microRNA-187 through targeting disabled homolog-2. Oncogene. 2011 Jul 4. doi: 10.1038/onc.2011.269. [Epub ahead of print].
73. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011;30:2587-94.
74. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004;20:53-70. (Pubitemid 39149915)
75. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011;49:443-5.
76. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful ? Clin Chem Lab Med 2011;49:521-5.
77. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
78. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009;114: 253-9.
79. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et al. MicroRNA microarray identifi es Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008;68:10307-14.
80. Shih KK, Qin LX, Tanner EJ, Zhou Q, Bisogna M, Dao F, et al. A microRNA survival signature (MiSS) for advanced ovarian cancer. Gynecol Oncol 2011;121:444-50.
81. Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010;49:577-84.
82. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, et al. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010;57:734-43.
83. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317:477. (Pubitemid 47196106)
84. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008;105:7004-9. (Pubitemid 351754520)
85. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007;67:10117-22. (Pubitemid 350070782)
86. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic signifi cance of CD3 + tumor-infi ltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-20. (Pubitemid 351174290)
87. Gracias DT, Katsikis PD. MicroRNAs: key components of immune regulation. Adv Exp Med Biol 2012;780:15-26.
88. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999;4:87-94. (Pubitemid 29202993)
89. Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacother 2001;2:109-24. (Pubitemid 32427718)
90. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009;113:249-55.
91. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18(Suppl 5):v3-8.
92. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drugresistant tumors: current views and new therapeutic prospective. J Cell Physiol 2006;207:571-81. (Pubitemid 43668220)
93. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxelbased treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2011;18:85-95.
94. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010;119: 125-30.
95. Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011;31:543-9.
96. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001;92:2837-44. (Pubitemid 33091920)
97. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-10. (Pubitemid 29042226)
98. Cooper BC, Ritchie JM, Broghammer CL, Coffi n J, Sorosky JI, Buller RE, et al. Preoperative serum vascular endothelial growth factor levels: signifi cance in ovarian cancer. Clin Cancer Res 2002;8:3193-7. (Pubitemid 35155030)
99. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey Biochim Biophys Acta 2007 1775 181-232. (Pubitemid 44911084)
100. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11:426-37.
101. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647-53.
102. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
103. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011;108:5003-8.
104. Qu H, Xu W, Huang Y, Yang S. Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev 2011;12:1117-25.
105. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.
106. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffi c 2002;3:321-30. (Pubitemid 34461042)
107. Hausler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived miRNA profi les as potential new tools for ovarian cancer screening. Br J Cancer 2010;103:693-700.
108. Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515.
109. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
110. Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER, et al. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 2002;62:5874-80. (Pubitemid 35204748)
111. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006;103:9136-41. (Pubitemid 43902545)
112. Bearfoot JL, Choong DY, Gorringe KL, Campbell IG. Genetic analysis of cancer-implicated microRNA in ovarian cancer. Clin Cancer Res 2008;14:7246-50.
113. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008;29:1963-6.
114. Garcia AI, Cox DG, Barjhoux L, Verny-Pierre C, Barnes D, Antoniou AC, et al. The rs2910164:G>C SNP in the MIR146A gene is not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2011 May 17. doi: 10.1002/humu.21539. [Epub ahead of print].
115. Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R. Association between hsa-mir-146a genotype and tumor age-ofonset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis 2010;31:2124-6.
116. Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, et al. Evaluation of SNPs in miR-146a, miR-196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat 2010;31:E1052-7.
117. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, et al. Correlation of p53 mutations with resistance to platinum- based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001;7:2984-97. (Pubitemid 32963815)
118. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C, et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008;14: 89- 96. (Pubitemid 351377982)
119. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007;120:371-8. (Pubitemid 46332500)
120. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, et al. An illegitimate microRNA target site within the 3'UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 2010;70:9641-9.
121. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9. (Pubitemid 351550859)
122. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease ?. Gene Ther 2006;13:496-502.
123. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007;4:721-6. (Pubitemid 47338166)
124. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specifi c interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007;212:285-92. (Pubitemid 47025616)
125. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
126. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23. (Pubitemid 350235025)
127. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. (Pubitemid 40343076)
128. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95. (Pubitemid 32193623)
129. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010;29:1103-13.
130. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, et al. Choice of normal ovarian control infl uences determination of differentially expressed genes in ovarian cancer expression profi ling studies. Clin Cancer Res 2003;9:4811-8. (Pubitemid 37323284)
131. Shahab SW, Matyunina LV, Mezencev R, Walker LD, Bowen NJ, Benigno BB, et al. Evidence for the complexity of micro- RNA-mediated regulation in ovarian cancer: a systems approach. PLoS One 2011;6:e22508.
132. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-52.
133. Benner SA. Extracellular'communicator RNA'. FEBS Lett 1988;233:225-8.